Privia Health Reports Fourth Quarter 2022 Financial Results
- FY 2022 Financial Results At or Above High End of Guidance with Practice Collections Growth of 49.1% compared to FY 2021
- New Market Entries announced in
Connecticut ,Delaware ,North Carolina andOhio - Launches Three New ACOs; Five ACOs now participating in MSSP Enhanced Track
- 2023 Capitated Lives Increase 38%+ to 40,600 Patients
Fourth Quarter
Total revenue for the fourth quarter of 2022 was
Non-GAAP adjusted net income was
Reconciliations of adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release.
Key operating and non-GAAP financial metrics include:
- Practice Collections for the fourth quarter of 2022 were
$634.8 million , compared to$513.2 million for the same period in 2021 (+23.7%). - Care Margin for the fourth quarter of 2022 was
$80.1 million , compared to$68.6 million for the same period in 2021 (+16.7%). - Platform Contribution for the fourth quarter of 2022 was
$39.1 million , compared to$27.8 million for the same period in 2021 (+40.7%). - Adjusted EBITDA for the fourth quarter of 2022 was
$14.3 million , compared to$7.5 million for the same period in 2021 (+89.5%). - Implemented Providers for the fourth quarter of 2022 were 3,606, compared to 3,317 at the end of the fourth quarter of 2021 (+8.7%).
- Value-Based Care Attributed Lives for the fourth quarter of 2022 were 856,000, compared to 786,000 at the end of the fourth quarter of 2021 (+8.9%).
“Privia Health delivered exceptional operating execution throughout 2022, culminating in excellent fourth quarter and full-year financial performance, with practice collections, care margin and adjusted EBITDA at or above the high end of our most recent financial guidance,” said
“Our long-term vision is to build one of the largest ambulatory care delivery care networks in the nation, and we are very excited about our entrance into four new states with leading provider partners in each of these geographies. In combination with growth in implemented providers and attributed lives across a number of value-based reimbursement programs, we expect this market expansion will drive continued top-line growth and increasing profitability in 2023 as we invest in our operations, talent and technology capabilities to support our long-term growth objectives,” Morris added.
Full Year
Total revenue for the full year ended
Non-GAAP adjusted net income was
Key operating and non-GAAP financial metrics include:
- Practice Collections for full-year 2022 were
$2.42 billion , compared to$1.63 billion for the same period in the prior year (+49.1%). - Care Margin was
$305.6 million , compared to$238.4 million for full-year 2021 (+28.2%). - Platform Contribution for full-year 2022 was
$148.5 million , compared to$107.6 million for the same period in the prior year (+38.1%). - Adjusted EBITDA was
$60.9 million , compared to$41.4 million for full-year 2021 (+47.1%).
Capital Resources and Cash Flow
The Company's balance sheet at
Net cash provided by operating activities for the year ended
New Market Entries / Health System Partnerships
On
On
On
On
These partnerships demonstrate Privia Health’s ability to replicate its operating model with uniquely different provider partners in geographies nationwide. New providers joining the Privia Platform will have access to a breadth of interoperable solutions and population health expertise to reduce administrative burden, enable care insights and promote collaboration.
New and Existing ACO Participation in MSSP
Effective
New Capitated Agreements
Effective,
Financial and Business Outlook a b c d
Privia Health’s full-year 2023 guidance, as outlined below, reflects management’s expected contribution from: existing market growth, recent entries into
FY 2022 | FY 2023 Guidance a | Y - Y % Change from FY 2022 | |||||||||||||||
($ in millions) | Actual | Low | High | Low | High | ||||||||||||
Implemented Providers | 3,606 | 4,050 | 4,150 | 12.3 | % | 15.1 | % | ||||||||||
Attributed Lives | 856,000 | 1,050,000 | 1,150,000 | 22.7 | % | 34.3 | % | ||||||||||
Practice Collections | $ | 2,424.1 | $ | 2,700 | $ | 2,850 | 11.4 | % | 17.6 | % | |||||||
GAAP Revenue | $ | 1,356.7 | $ | 1,550 | $ | 1,650 | 14.3 | % | 21.6 | % | |||||||
Care Margin | $ | 305.6 | $ | 350 | $ | 365 | 14.5 | % | 19.4 | % | |||||||
Platform Contribution | $ | 148.5 | $ | 160 | $ | 168 | 7.7 | % | 13.1 | % | |||||||
Adjusted EBITDA c | $ | 60.9 | $ | 70 | $ | 74 | 15.0 | % | 21.6 | % | |||||||
- Capital expenditures are expected to be less than
$1 million in full-year 2023 - Adjusted EBITDA guidance includes approximately
$8-10 million in start-up costs for new geographies and ACOs - Approximately 80-90% of Adjusted EBITDA expected to convert to free cash flow (defined as net cash provided by operating activities less capital expenditures) in FY 2023
- Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of operating income, net income, and net cash provided by operating activities. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.
- See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.
Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly financial press releases.
- Any slight variations in totals due to rounding.
Webcast and Conference Call Information
The Company will host a conference call on
This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.
About
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Our platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Non-GAAP Financial Measures
The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in
The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.
In the third quarter of 2022, we changed the definition of Adjusted EBITDA to exclude employer taxes on equity vesting/exercise. In prior periods, this amount was considered de minimis and the Adjusted EBITDA amounts were not adjusted. Employer payroll tax expense related to employee stock transactions are tied to the vesting or exercise of underlying equity awards and the price of our common stock at the time of vesting, which varies in amount from period to period and is dependent on market forces that are often beyond our control. As a result, management excludes this item from our internal operating forecasts and models. Management believes that non-GAAP measures adjusted for employer payroll taxes on employee stock transactions provide investors with a basis to measure our core performance against the performance of other companies without the variability created by employer payroll taxes on employee stock transactions as a result of the stock price at the time of employee exercise. The presentation of Adjusted EBITDA and Adjusted Net Income for the three and twelve months ended
Safe Harbor Statement
The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-K is filed with the
Factors related to these risks and uncertainties include, but are not limited to: compliance with applicable healthcare laws and government regulations in the heavily regulated industry in which the Company operates; the Company’s dependence on relationships with its medical groups, some of which the Company does not own; the Company’s growth strategy, which may not prove viable and the Company may not realize expected results; the Company’s inability to enter into a definitive agreement for its partnership in
Contact: |
SVP, |
[email protected] |
817.783.4841 |
Condensed Consolidated Statements of Operations (a)
(in thousands, except share and per share data)
For the Three Months Ended |
For the Years Ended |
||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
(unaudited) | (unaudited) | ||||||||||||||
Revenue | $ | 364,424 | $ | 275,333 | $ | 1,356,660 | $ | 966,220 | |||||||
Operating expenses: | |||||||||||||||
Provider expense | 284,368 | 206,722 | 1,051,040 | 727,827 | |||||||||||
Cost of platform | 43,343 | 43,724 | 170,838 | 174,731 | |||||||||||
Sales and marketing | 5,173 | 3,800 | 19,741 | 22,750 | |||||||||||
General and administrative | 28,156 | 39,321 | 129,592 | 255,884 | |||||||||||
Depreciation and amortization | 1,135 | 1,113 | 4,571 | 2,464 | |||||||||||
Total operating expenses | 362,175 | 294,680 | 1,375,782 | 1,183,656 | |||||||||||
Operating income (loss) | 2,249 | (19,347 | ) | (19,122 | ) | (217,436 | ) | ||||||||
Interest (income) expense, net | (1,152 | ) | 185 | (542 | ) | 1,070 | |||||||||
Income (loss) before benefit from income taxes | 3,401 | (19,532 | ) | (18,580 | ) | (218,506 | ) | ||||||||
Benefit from income taxes | (13,447 | ) | (7,643 | ) | (6,516 | ) | (27,857 | ) | |||||||
Net income (loss) | 16,848 | (11,889 | ) | (12,064 | ) | (190,649 | ) | ||||||||
Less: (loss) income attributable to non-controlling interests | (928 | ) | 90 | (3,479 | ) | (2,419 | ) | ||||||||
Net income (loss) attributable to |
$ | 17,776 | $ | (11,979 | ) | $ | (8,585 | ) | $ | (188,230 | ) | ||||
Net income (loss) per share attributable to |
$ | 0.16 | $ | (0.11 | ) | $ | (0.08 | ) | $ | (1.83 | ) | ||||
Net income (loss) per share attributable to |
$ | 0.14 | $ | (0.11 | ) | $ | (0.08 | ) | $ | (1.83 | ) | ||||
Weighted average common shares outstanding – basic | 114,364,180 | 107,034,298 | 110,695,266 | 102,952,370 | |||||||||||
Weighted average common shares outstanding – diluted | 124,142,657 | 107,034,298 | 110,695,266 | 102,952,370 |
(a) Any slight variations in totals due to rounding.
Condensed Consolidated Balance Sheets (a)
(in thousands)
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 347,992 | $ | 320,577 | |||
Accounts receivable | 189,604 | 117,402 | |||||
Prepaid expenses and other current assets | 14,366 | 8,697 | |||||
Total current assets | 551,962 | 446,676 | |||||
Non-current assets: | |||||||
Property and equipment, net | 3,386 | 4,502 | |||||
Right-of-use asset | 8,089 | 9,634 | |||||
Intangible assets, net | 57,387 | 59,738 | |||||
126,938 | 127,938 | ||||||
Deferred tax asset | 40,368 | 33,364 | |||||
Other non-current assets | 4,683 | 4,521 | |||||
Total non-current assets | 240,851 | 239,697 | |||||
Total assets | $ | 792,813 | $ | 686,373 | |||
Liabilities and stockholders’ equity | |||||||
Current liabilities: | |||||||
Accounts payable and accrued expenses | $ | 52,837 | $ | 45,985 | |||
Provider liability | 208,424 | 140,708 | |||||
Current portion of note payable | — | 875 | |||||
Operating lease liabilities, current | 3,013 | 2,893 | |||||
Total current liabilities | 264,274 | 190,461 | |||||
Non-current liabilities: | |||||||
Note payable, net of current portion | — | 31,688 | |||||
Operating lease liabilities, non-current | 8,490 | 11,043 | |||||
Other non-current liabilities | 1,000 | 3,000 | |||||
Total non-current liabilities | 9,490 | 45,731 | |||||
Total liabilities | 273,764 | 236,192 | |||||
Commitments and contingencies | |||||||
Stockholders’ equity: | |||||||
Common stock | 1,148 | 1,078 | |||||
Additional paid-in capital | 714,639 | 633,902 | |||||
Accumulated deficit | (216,693 | ) | (208,108 | ) | |||
499,094 | 426,872 | ||||||
Non-controlling interest | 19,955 | 23,309 | |||||
Total stockholders’ equity | 519,049 | 450,181 | |||||
Total liabilities and stockholders’ equity | $ | 792,813 | $ | 686,373 |
(a) Any slight variations in totals are due to rounding.
Consolidated Statement of Cash Flows (a)
(in thousands)
For the Years Ended |
|||||||
2022 | 2021 | ||||||
Cash flows from operating activities | |||||||
Net loss | $ | (12,064 | ) | $ | (190,649 | ) | |
Adjustments to reconcile loss to net cash provided by operating activities: | |||||||
Depreciation | 1,220 | 1,152 | |||||
Amortization of intangibles | 3,351 | 1,312 | |||||
Amortization of debt issuance costs | 687 | 157 | |||||
Stock-based compensation | 67,359 | 253,531 | |||||
Deferred tax benefit | (7,004 | ) | (28,411 | ) | |||
Changes in asset and liabilities: | |||||||
Accounts receivable | (72,202 | ) | (14,642 | ) | |||
Prepaid expenses and other current assets | (5,669 | ) | (1,269 | ) | |||
Other non-current assets and right-of-use asset | 1,383 | (9,680 | ) | ||||
Accounts payable and accrued expenses | 6,852 | 1,262 | |||||
Provider liability | 67,716 | 33,897 | |||||
Operating lease liabilities | (2,433 | ) | 13,936 | ||||
Other long-term liabilities | (2,000 | ) | (5,538 | ) | |||
Net cash provided by operating activities | 47,196 | 55,058 | |||||
Cash flows from investing activities | |||||||
Purchases of property and equipment | (104 | ) | (547 | ) | |||
Business acquisitions, net of cash acquired | — | (32,228 | ) | ||||
Net cash used in investing activities | (104 | ) | (32,775 | ) | |||
Cash flows from financing activities | |||||||
Proceeds from initial public offering | — | 223,685 | |||||
Payments of underwriting fees, net of discounts and offering costs | — | (12,691 | ) | ||||
Proceeds from non-controlling interest | 125 | — | |||||
Repayment of note payable | (33,250 | ) | (875 | ) | |||
Proceeds from exercised stock options | 13,448 | 3,829 | |||||
Debt issuance costs | — | (287 | ) | ||||
Net cash (used in) provided by financing activities | (19,677 | ) | 213,661 | ||||
Net increase in cash and cash equivalents | 27,415 | 235,944 | |||||
Cash and cash equivalents at beginning of period | 320,577 | 84,633 | |||||
Cash and cash equivalents at end of period | $ | 347,992 | $ | 320,577 | |||
Supplemental disclosure of cash flow information: | |||||||
Interest paid | $ | 713 | $ | 888 | |||
Income taxes paid | $ | 307 | $ | 504 |
(a) Any slight variations in totals are due to rounding.
Additional Financial Information
Revenues disaggregated by source:
For the Three Months Ended |
For the Years Ended |
||||||||||||||
(Dollars in Thousands) | 2022 | 2021 | 2022 | 2021 | |||||||||||
FFS-patient care | $ | 231,624 | $ | 221,874 | $ | 869,165 | $ | 772,482 | |||||||
FFS-administrative services | 23,018 | 21,643 | 94,929 | 68,805 | |||||||||||
Capitated revenue | 57,687 | — | 218,463 | — | |||||||||||
Shared savings | 42,319 | 20,971 | 132,615 | 83,016 | |||||||||||
Care management fees (PMPM) | 8,023 | 9,183 | 35,541 | 36,503 | |||||||||||
Other revenue | 1,754 | 1,662 | 5,947 | 5,414 | |||||||||||
Total Revenue | $ | 364,425 | $ | 275,333 | $ | 1,356,660 | $ | 966,220 | |||||||
The Company’s liabilities for unpaid medical claims under at-risk capitation arrangements:
(Dollars in Thousands) | ||||
Balance at |
$ | — | ||
Incurred health care costs: | ||||
Current year | 218,199 | |||
Prior years | — | |||
Total claim incurred | 218,199 | |||
Claims paid: | ||||
Current year | (189,582 | ) | ||
Prior year | — | |||
Total claims paid | (189,582 | ) | ||
Adjustments to other claims-related liabilities | — | |||
Balance at |
$ | 28,617 |
Key Metrics and Non-GAAP Financial Measures
Key Metrics(a)
For the Three Months Ended |
For the Years Ended |
|||||||||||||||
(unaudited; $ in millions) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
Implemented Providers(1) | 3,606 | 3,317 | 3,606 | 3,317 | ||||||||||||
Attributed Lives(2) | 856,000 | 786,000 | 856,000 | 786,000 | ||||||||||||
Practice Collections(3) | $ | 634.8 | $ | 513.2 | $ | 2,424.1 | $ | 1,626.1 | ||||||||
(1) Implemented Providers is defined as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by |
||||||||||||||||
(2) Attributed Lives are defined as any patient that a payer deems attributed to |
||||||||||||||||
(3) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups. | ||||||||||||||||
(a) Any slight variations in totals are due to rounding. |
Non-GAAP Financial Measures (4)(a)
For the Three Months Ended |
For the Years Ended |
|||||||||||||||
(unaudited; $ in thousands) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
Care Margin | $ | 80,056 | $ | 68,611 | $ | 305,620 | $ | 238,393 | ||||||||
Platform Contribution | 39,089 | 27,788 | 148,540 | 107,550 | ||||||||||||
Platform Contribution Margin | 48.8 | % | 40.5 | % | 48.6 | % | 45.1 | % | ||||||||
Adjusted EBITDA | 14,265 | 7,528 | 60,852 | 41,377 | ||||||||||||
Adjusted EBITDA Margin | 17.8 | % | 11.0 | % | 19.9 | % | 17.4 | % | ||||||||
(4) In addition to results reported in accordance with GAAP,
|
||||||||||||||||
(a) Any slight variations in totals are due to rounding. |
Reconciliation of Operating Income (Loss) to Care Margin(a)
For the Three Months Ended |
For the Years Ended |
|||||||||||||||
(unaudited; $ in thousands) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
Operating income (loss) | $ | 2,249 | $ | (19,347 | ) | $ | (19,122 | ) | $ | (217,436 | ) | |||||
Depreciation and amortization | 1,135 | 1,113 | 4,571 | 2,464 | ||||||||||||
General and administrative | 28,156 | 39,321 | 129,592 | 255,884 | ||||||||||||
Sales and marketing | 5,173 | 3,800 | 19,741 | 22,750 | ||||||||||||
Cost of platform | 43,343 | 43,724 | 170,838 | 174,731 | ||||||||||||
Care margin | $ | 80,056 | $ | 68,611 | $ | 305,620 | $ | 238,393 | ||||||||
(a) Any slight variations in totals are due to rounding. |
Reconciliation of Operating Income (Loss) to Platform Contribution(a)
For the Three Months Ended |
For the Years Ended |
|||||||||||||||
(unaudited; $ in thousands) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
Operating income (loss) | $ | 2,249 | $ | (19,347 | ) | $ | (19,122 | ) | $ | (217,436 | ) | |||||
Depreciation and amortization | 1,135 | 1,113 | 4,571 | 2,464 | ||||||||||||
General and administrative | 28,156 | 39,321 | 129,592 | 255,884 | ||||||||||||
Sales and marketing | 5,173 | 3,800 | 19,741 | 22,750 | ||||||||||||
Stock-based compensation(5) | 2,376 | 2,901 | 13,758 | 43,888 | ||||||||||||
Platform contribution | $ | 39,089 | $ | 27,788 | $ | 148,540 | $ | 107,550 | ||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||
(5) Amount represents stock-based compensation expense included under Cost of Platform. |
Reconciliation of Net Income (Loss) to Adjusted EBITDA(a)
For the Three Months Ended |
For the Years Ended |
|||||||||||||||
(unaudited; $ in thousands) | 2022 | 2021 | 2022 | 2021 | ||||||||||||
Net income (loss) | $ | 17,776 | $ | (11,979 | ) | $ | (8,585 | ) | $ | (188,230 | ) | |||||
Net (loss) income attributable to non-controlling interests | (928 | ) | 90 | (3,479 | ) | (2,419 | ) | |||||||||
Benefit from income taxes | (13,447 | ) | (7,643 | ) | (6,516 | ) | (27,857 | ) | ||||||||
Interest (income) expense | (1,152 | ) | 185 | (542 | ) | 1,070 | ||||||||||
Depreciation and amortization | 1,135 | 1,113 | 4,571 | 2,464 | ||||||||||||
Stock-based compensation | 9,175 | 25,071 | 67,359 | 253,531 | ||||||||||||
Other expenses(6) | 1,706 | 691 | 8,044 | 2,818 | ||||||||||||
Adjusted EBITDA | $ | 14,265 | $ | 7,528 | $ | 60,852 | $ | 41,377 | ||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||
(6) Other expenses include employer taxes on equity vesting/exercises, legal, severance and certain non-recurring costs. Employer taxes on equity vesting/exercises of |
Reconciliation of Net Income (Loss) to Adjusted Net Income and Adjusted Net Income Per Share(a)
For the Three Months Ended |
For the Years Ended |
||||||||||||||
(unaudited; $ in thousands) | 2022 | 2021 | 2022 | 2021 | |||||||||||
Net income (loss) | $ | 17,776 | $ | (11,979 | ) | $ | (8,585 | ) | $ | (188,230 | ) | ||||
Stock-based compensation | 9,175 | 25,071 | 67,359 | 253,531 | |||||||||||
Intangible amortization expense | 842 | 830 | 3,351 | 1,312 | |||||||||||
Benefit from income tax | (13,447 | ) | (7,643 | ) | (6,516 | ) | (27,857 | ) | |||||||
Other expenses(6) | 1,706 | 691 | 8,044 | 2,818 | |||||||||||
Adjusted net income attributable to |
$ | 16,052 | $ | 6,970 | $ | 63,653 | $ | 41,574 | |||||||
Adjusted net income per share attributable to |
$ | 0.14 | $ | 0.07 | $ | 0.58 | $ | 0.40 | |||||||
Adjusted net income per share attributable to |
$ | 0.13 | $ | 0.06 | $ | 0.52 | $ | 0.36 | |||||||
Weighted average common shares outstanding – basic | 114,364,180 | 107,034,298 | 110,695,266 | 102,952,370 | |||||||||||
Weighted average common shares outstanding – diluted | 124,142,657 | 120,690,458 | 122,952,853 | 114,830,915 | |||||||||||
(a) Any slight variations in totals due to rounding. | |||||||||||||||
(6) Other expenses include employer taxes on equity vesting/exercises, legal, severance and certain non-recurring costs. Employer taxes on equity vesting/exercises of |
Source:
Investment firm administrator handed 3-year sentence for theft from company and clients
Clover Health Reports Fourth Quarter and Full Year 2022 Financial Results
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News